Insiders who reported open-market trades in the last 12 months at the companies Louise Rodino-Klapac files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Ian Michael Estepan - $294K in SRPT purchases and sales in the last 12 months
Stephen Mayo - $123K in SRPT purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Louise Rodino-Klapac is a corporate insider, tracked as President, R&D and Tech Ops of Sarepta Therapeutics, Inc. (SRPT). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Louise Rodino-Klapac submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Louise Rodino-Klapac is President, R&D and Tech Ops of Sarepta Therapeutics, Inc. (SRPT). 9 SEC Form 4 filings on record going back to 2024, most recently on 9 September 2026.
Recent transactions
11
The latest 11 SEC Form 4 transactions reported by Louise Rodino-Klapac.
InsiderAlpha's records for Louise Rodino-Klapac go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
